MX2016004328A - Inmunopotenciador. - Google Patents

Inmunopotenciador.

Info

Publication number
MX2016004328A
MX2016004328A MX2016004328A MX2016004328A MX2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A MX 2016004328 A MX2016004328 A MX 2016004328A
Authority
MX
Mexico
Prior art keywords
immunopotentiator
glucan
poly
modified
active ingredient
Prior art date
Application number
MX2016004328A
Other languages
English (en)
Inventor
Yoichiro Koshi
Joonsik Park
Jiao Lu
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of MX2016004328A publication Critical patent/MX2016004328A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/593—Polyesters, e.g. PLGA or polylactide-co-glycolide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55583—Polysaccharides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se proporciona un inmunopotenciador que comprende, como un ingrediente activo, un ß-glucano modificado el cual ß-glucano y el poli (ácido hidroxi) se unen covalentemente. El inmunopotenciador puede mejorar fuertemente la acción de inmunopotenciación del ß-glucano.
MX2016004328A 2013-10-09 2014-10-09 Inmunopotenciador. MX2016004328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013212103 2013-10-09
PCT/JP2014/077038 WO2015053354A1 (ja) 2013-10-09 2014-10-09 免疫賦活化剤

Publications (1)

Publication Number Publication Date
MX2016004328A true MX2016004328A (es) 2016-07-11

Family

ID=52813169

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016004328A MX2016004328A (es) 2013-10-09 2014-10-09 Inmunopotenciador.

Country Status (14)

Country Link
US (1) US10556004B2 (es)
EP (1) EP3056208B1 (es)
JP (1) JP6146676B2 (es)
KR (1) KR102343005B1 (es)
CN (1) CN105611936B (es)
AU (1) AU2014332835B2 (es)
BR (1) BR112016007130B1 (es)
CA (1) CA2926720A1 (es)
DK (1) DK3056208T3 (es)
ES (1) ES2887367T3 (es)
MX (1) MX2016004328A (es)
PL (1) PL3056208T3 (es)
RU (1) RU2702987C2 (es)
WO (1) WO2015053354A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110237249A (zh) * 2018-03-09 2019-09-17 南开大学 特异靶向树突状细胞的新型铝佐剂及在疫苗制备上的应用
CN117813112A (zh) 2021-08-30 2024-04-02 东丽株式会社 免疫原性增强用组合物
CA3230661A1 (en) 2021-08-30 2023-03-09 Toray Industries, Inc. Composition for enhancing immunogenicity
CA3232439A1 (en) 2021-09-16 2023-03-23 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3871892A (en) * 1972-12-18 1975-03-18 Hayashibara Biochem Lab Shaped bodies of pullulan esters and their use
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
EP0640348A1 (en) * 1993-07-26 1995-03-01 Akzo Nobel N.V. Oil-based and water-based adjuvant mixture
JP4091136B2 (ja) 1997-01-17 2008-05-28 キリンフードテック株式会社 免疫賦活剤
US20040057958A1 (en) * 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
EP1602377B1 (en) * 2003-03-07 2011-08-10 Aureo Co., Ltd. Composition containing beta-glucan and constipation-relieving drug, immunopotentiator and skin moistening agent using the composition
JP5138954B2 (ja) * 2006-03-09 2013-02-06 独立行政法人科学技術振興機構 両親媒性高分子複合体
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
ES2599908T3 (es) 2007-11-26 2017-02-06 Glaxosmithkline Biologicals Sa Glucanos beta-1,3-enlazados conjugados
CA2706617A1 (en) 2007-11-26 2009-06-25 Novartis Ag Adjuvanted glucans
US8815253B2 (en) 2007-12-07 2014-08-26 Novartis Ag Compositions for inducing immune responses
AU2009216216B2 (en) * 2008-02-22 2013-11-07 Toray Industries, Inc. Microparticles and pharmaceutical compositions thereof
JP5429707B2 (ja) 2008-03-27 2014-02-26 国立大学法人群馬大学 微粒子およびその製造方法
DK2402032T3 (da) 2009-02-27 2019-11-04 Toray Industries Immunogen sammensætning
CN103052402B (zh) * 2010-08-26 2015-08-12 东丽株式会社 免疫原性组合物
GB201020193D0 (en) * 2010-11-29 2011-01-12 Biotec Pharmacon Asa Glucan compositions
JP2013067709A (ja) 2011-09-21 2013-04-18 Gunze Ltd ヒアルロン酸修飾物

Also Published As

Publication number Publication date
WO2015053354A1 (ja) 2015-04-16
KR20160060072A (ko) 2016-05-27
AU2014332835B2 (en) 2019-07-25
CA2926720A1 (en) 2015-04-16
CN105611936B (zh) 2021-08-20
EP3056208A4 (en) 2017-06-14
BR112016007130A2 (pt) 2020-06-16
JP6146676B2 (ja) 2017-06-14
AU2014332835A1 (en) 2016-04-28
US10556004B2 (en) 2020-02-11
CN105611936A (zh) 2016-05-25
BR112016007130B1 (pt) 2023-01-31
PL3056208T3 (pl) 2021-12-20
DK3056208T3 (en) 2021-11-15
RU2016116786A (ru) 2017-11-15
JPWO2015053354A1 (ja) 2017-03-09
EP3056208A1 (en) 2016-08-17
RU2016116786A3 (es) 2018-08-01
KR102343005B1 (ko) 2021-12-24
RU2702987C2 (ru) 2019-10-15
EP3056208B1 (en) 2021-08-18
US20160256543A1 (en) 2016-09-08
ES2887367T3 (es) 2021-12-22

Similar Documents

Publication Publication Date Title
AU2018256640A1 (en) Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
PH12016500486A1 (en) Aza-pyridone compounds and uses thereof
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
EP3043732A4 (en) Systems, methods and devices for treatment of target tissue
MX2015009106A (es) Composiciones de solución sólida y su uso en el tratamiento del dolor intenso.
MX2016008448A (es) Conjugados de var2csa-farmaco.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
PH12016500720A1 (en) Stable formulation of insulin glulisine
TN2015000411A1 (en) Ceftolozane antibiotic compositions
MY172699A (en) Implantable medical devices with increased immune tolerance, and methods for making and implanting
MX2015011837A (es) Co-cristale de pirimetanil y tetracarboximida de ditiina seleccionada.
MX2017007577A (es) Compuestos de dihidropirimidin-2-ona y su uso medico.
MX2017004655A (es) Compuestos de hidroxil purinas y aplicaciones de estos.
MX2016004328A (es) Inmunopotenciador.
MX2016015261A (es) Dispersion solida de allisartan isoproxilo y su composicion.
MX2018005085A (es) Nanoparticulas terapeuticas que comprenden un agente terapeutico y metodos de fabricacion y uso de las mismas.
MX2016004078A (es) Formulacion de atazanavir y cobicistat para el tratamiento del virus de inmunodeficiencia humana (vih).
TWD166675S (zh) 電連接器
WO2013162981A3 (en) Breast implant spacers for the treatment of periprosthetic breast implant infections
MX2017006712A (es) Inhibidor de produccion de metaloproteinasa de matriz.
MX2015016603A (es) Composiciones de corticosteroides.
IN2014DN06617A (es)
MY186332A (en) Pentosidine production inhibitor
MX2016016612A (es) Formulaciones estables de undecanoato de testosterona.
UA90039U (en) Ethyl ester of 6-thioxo-3-(4-fluorophenyl)-7-cyano-1,3,4,6-2h-pyrido[1,2-a][1,3,5]triazine-9-carboxylic acid